Patients with a subtype of glioblastoma who received a combination treatment of a PARP inhibitor and standard chemotherapy did not demonstrate improved survival compared to chemotherapy and placebo, according to a recent clinical trial published in JAMA Oncology.
This study examines a modified progressive disease classification and its association with postprogression survival in patients treated with atezolizumab across various solid tumors.
Taletrectinib demonstrated favorable efficacy and tolerability data in the TRUST-I and TRUST-II trials for the treatment of patients with advanced non–small cell lung cancer.
NCCR collects data and publishes statistics to better understand the causes, outcomes, effective treatments, and later effects of cancer among children, adolescents, and young adults…
Almost every patient with a cancer diagnosis has asked me, “How should I change my diet?” Yesterday’s Plenary Scientific Session, Ketogenic Diet Enhances CAR-T Cell…
Dr. David Barbie and his team will receive a 4-year, $2.5 million grant to support their research on immune-based approaches to target drug-resistant cancer cells.
During a Case-Based Roundtable® event, Komal Jhaveri, MD, FACP, discussed dosing and toxicity concerns with the approved CDK4/6 inhibitor regimens used in the adjuvant setting for…
In an industry that set its sights on reshaping cancer detection, GRAIL Inc. had the appearance of a pioneer. To access this subscriber-only content please…
Aditya Bardia, MD, of UCLA David Geffen School of Medicine, Los Angeles, presents the additional analysis of the efficacy and safety of trastuzumab deruxtecan vs…
Catch up with our live social media coverage of indolent and mantle cell lymphoma, from the American Society of Hematology (ASH) 2024 Meeting and Exposition.
